Personalized Healthcare in Autoimmune Diseases - Genomic Biomarkers for Pharmaceutical Development - page 67

[23] Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev
2004;202:8-32.
[24] Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 2005;5:375-86.
[25] van Boxel-Dezaire AHH, Rani MRS, Stark GR. Complex modulation of cell type-speciic signaling in response
to type i interferons. Immunity 2006;25:361-72.
[26] Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis
patients is associated with disease activity. Mol Med 2007;13(1-2):59-68.
[27] Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythemato-
sus blood. J Exp Med 2003;197(6):711-23.
[28] Han GM, Chen SL, Shen N, et al. Analysis of gene expression proiles in human systemic lupus erythematosus
using oligonucleotide microarray. Genes Immun 2003;4(3):177-86.
[29] Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and relects
disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56(11):3784-92.
[30] Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis
and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70(11):2029-36.
[31] Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha / beta-inducible genes and downstream
effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Arthritis Rheum 2009;60(6):1785-96.
[32] Merrill JT, Wallace DJ, Petri M, et al. Safety proile and clinical activity of sifalimumab, a fully human anti-
interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicenter, double-blind
randomised study. Ann Rheum Dis 2011;70(11):1905-13.
[33] McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic
lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis
Rheum 2012;64(11):3666-76.
[34] Higgs BW, Zhu W, Morehouse C, et al. Sifalimumab, an anti-IFN-α mAb, shows target suppression of a
type I IFN signature in blood and muscle of dermatomyositis and polymyositis patients. Ann Rheum Dis
2013;February [Epub ahead of print].
[35] Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon β is associated with type 1
interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2010;70(5):831-6.
[36] Cappelletti C, Baggi F, Zolezzi F, et al. Type I interferon and Toll-like receptor expression characterizes inlam-
matory myopathies. Neurology 2011;76(24):2079-88.
[37] Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II
cytokine receptor complex. Nat Immunol 2003;4(1):69-77.
[38] Wang B, Higgs BW, Chang L, et al. Pharmacogenomic biomarker development and translational simulations
to bridge clinical indications for an anti-interferon alpha receptor antibody. Clin Pharm Ther 2013;Feb. http://
dx.doi.org/10.1038 / clpt.2013.35 .
[39] Abbas AK, Lichtman AH, Pillai S. B cell activation and antibody production. Cellular and Molecular
Immunology. 6th ed. Philadelphia, PA: Saunders Elsevier; 2010. pp. 215-241.
[40] Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal
antibody to CD20. Blood 1994;83(2):435-45.
[41] Chynes RA, Towers TL, Presta LG. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Nat Med 2006;6:443-6.
[42] Owczarczyk K, Lal P, Abbas AR, et al. A plasmablast biomarker for non-response to antibody therapy to CD20
in rheumatoid arthritis. Sci Transl Med 2011;3(101):101ra92. http://dx.doi.org/10.1126 / scitranslmed.3002432 .
[43] De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Eficacy of selective B cell blockade in the treat-
ment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46(8):2029-33.
[44] Edwards JC, Szczepanski L, Szechinski J, et al. Eficacy of B-cell-targeted therapy with rituximab in patients
with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81.
[45] Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte
stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell deple-
tion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54(3):723-32.
[46] Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after deple-
tion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(2):613-20.